Abstract：
Aim: The prognosis of high-risk, locally advanced cervical cancer (LACC) remains poor following concurrent chemoradiotherapy (CCRT). We investigated whether the effect of CCRT can be enhanced by programmed cell death protein 1 (PD-1) inhibitor. Methods: A retrospective cohort study was conducted to compare the efficacy and safety of CCRT group (n = 82) and PD-1 inhibitor plus CCRT group (n = 70). Results: Compared with the CCRT group, the PD-1 inhibitor plus CCRT group had significantly higher objective response rate, median progression-free survival, leukopenia and fatigue. The addition of PD-1 inhibitor to CCRT showed a favorable trend in overall survival without statistical significance. Conclusion: PD-1 inhibitor plus CCRT presented a significant survival benefit and a manageable safety profile in high-risk LACC.
[Box: see text].
[Box: see text].
摘要：
目的：高危人群的预后，局部晚期宫颈癌(LACC)在同步放化疗(CCRT)后仍然较差.我们研究了程序性细胞死亡蛋白1（PD-1）抑制剂是否可以增强CCRT的作用。方法：回顾性队列研究比较CCRT组（n=82）和PD-1抑制剂加CCRT组（n=70）的疗效和安全性。结果:与CCRT组相比,PD-1抑制剂加CCRT组的客观缓解率明显更高，中位无进展生存期，白细胞减少和疲劳。在CCRT中添加PD-1抑制剂显示出总体生存的有利趋势，但无统计学意义。结论：PD-1抑制剂联合CCRT在高危LACC中具有显著的生存获益和可控制的安全性。
[方框：见正文]。
[方框：见正文]。
